Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Splitomicin SCHEMBL29570541 | 1.00 | SIRT1 (1.00) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL13893535 | 0.90 | SIRT1 (0.81) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL14677465 | 0.84 | SIRT1 (0.72) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL13893534 | 0.79 | KDM4E (0.65) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL9121753 | 0.78 | HPGD (0.64) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL9123291 | 0.78 | HPGD (0.64) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL8313602 | 0.75 | KDM4E (0.60) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL30522627 | 0.75 | KDM4E (0.60) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL414928 | 0.75 | HSD17B10 (0.59) | SIRT1KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL29688038 | 0.75 | HSD17B10 (0.59) | SIRT1KDM4ECYP1A2GLACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-12-01 | — | — | US | claimed |
| US-9168316-B2 | Methods for treating obesity | GU YANSONG (US) | 2015-10-27 | — | — | US | claimed |
| US-20140322136-A1 | METHODS FOR TREATING OBESITY | GU YANSONG (US) | 2014-10-30 | — | — | US | claimed |
| US-20110262362-A1 | METHODS FOR TREATING OBESITY | GU YANSONG | 2011-10-27 | — | — | US | claimed |
| WO-2010042868-A2 | METHODS FOR TREATING OBESITY | UNIVERSITY OF WASHINGTON (US) | 2010-04-15 | — | — | WO | claimed |
| US-20060194769-A1 | Small molecules that reduce fungal growth | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-31 | — | — | US | claimed |
| WO-2006081327-A2 | SMALL MOLECULES THAT REDUCE FUNGAL GROWTH | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-03 | — | — | WO | claimed |
| US-20050079995-A1 | Methods for inhibiting deacetylase activity | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-04-14 | — | — | US | claimed |
| WO-2003046207-A2 | METHODS FOR INHIBITING DEACETYLASE ACTIVITY | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2003-06-05 | — | — | WO | claimed |
| EP-4194548-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12408605-B2 | Haploid embryogenesis | STICHTING WAGENINGEN RESEARCH (NL) | 2025-09-09 | — | — | US | disclosed |
| US-20250218546-A1 | METHODS AND COMPOSITIONS FOR SIRT1 EXPRESSION AS A MARKER FOR ENDOMETRIOSIS AND SUBFERTILITY | Prisma Health | 2025-07-03 | — | — | US | disclosed |
| US-20240100079-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS IN THE INNER EAR OF ADULT MAMMALS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-28 | — | — | US | disclosed |
| EP-4288066-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS IN THE INNER EAR OF ADULT MAMMALS | Massachusetts Eye and Ear Infirmary (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2006081327-A2 | SMALL MOLECULES THAT REDUCE FUNGAL GROWTH | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006081327-A2 | SMALL MOLECULES THAT REDUCE FUNGAL GROWTH | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20050079995-A1 | Methods for inhibiting deacetylase activity | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-04-14 | — | — | US | disclosed |
| WO-2003046207-A2 | METHODS FOR INHIBITING DEACETYLASE ACTIVITY | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003046207-A2 | METHODS FOR INHIBITING DEACETYLASE ACTIVITY | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-1997014685-A1 | PYRIMIDINE DERIVATIVES | GYÓGYSZERKUTATÓ INTÉZET KFT (HU) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194769-A1 | Small molecules that reduce fungal growth | ERG28, DPM1, CYP51A1 | SIRT1 2725/4885KDM4E 2135/4885CYP1A2 1362/4885 |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | SIRT1 4028/4885KDM4E 127/4885CYP1A2 4732/4885 |
| US-20050079995-A1 | Methods for inhibiting deacetylase activity | SIRT2, SIRT1, HDAC1 | SIRT1 2/4885KDM4E 1476/4885CYP1A2 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.